NEW YORK/LONDON (Reuters) - Merck & Co Inc is looking to sell a big portfolio of mature drugs that could fetch more than $15 billion, according to people familiar with the matter, as the U.S. drugmaker continues to streamline businesses to focus on high-growth areas.
MERCK (MRK.NY) which is also in the process of selling its $14 billion consumer healthcare unit, is working with an investment bank on the potential sale of the off-patent drugs, which could draw interest from generic drugmakers, the people said.
The sale processes underscore efforts by large drugmakers to shed smaller divisions they view as noncore so they can better focus on their mainstay products. They have shown new willingness to consider large asset swaps with rivals to exit weaker businesses and bolster core areas where they are already top players.
Sanofi SA
Representatives for Merck could not be immediately reached for comment. The sources asked not to be named because the matter is not public.
(Reporting by Soyoung Kim, Olivia Oran in New York and Sophie Sassard in London; Editing by Prudence Crowther)
Relacionados
- AMPL.- Cañete advierte al PSOE de que debería haber empezado la campaña pidiendo perdón "por todo el daño hecho"
- AV.- Cañete advierte al PSOE que debería haber empezado la campaña pidiendo perdón "por todo el daño hecho"
- Médicos se concentran en la Maternidad de O'Donnell pidiendo que el feto sea considerado un paciente
- Un concejal del PP apoya una moción del PSOE pidiendo la retirada del anteproyecto de Ley del Aborto
- Un "grupo anticorrupción" seguirá "allí donde vaya" al alcalde de "Santiago de Corruptela" pidiendo su dimisión
